Science of Plasma

What is Plasma?

Plasma is the Fourth State of Matter…

Plasma Classification

What is Canady Helios™ Cold Plasma (CHCP)?

The Canady Cold Plasma spray is a non-thermal process that triggers chemical-molecular changes in cancer cells, leading to Apoptosis (Cell Death) while healthy human tissue remains unharmed.1

Canady Helios™ Cold Plasma offers Key Benefits to your Patients

  • Only One Application Required
  • The Plasma Application Occurs During your Surgery and only takes 5-7 minutes
  • Safe – No Side Effects

The Application of Canady Helios™ Cold Plasma

STEP 1
Cancerous Tumor Located in Breast

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 4
Step Four: Research Indicates that Microscopic Cancer Cells are Selectively Targeted with CHCP 5

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, leading to Apoptosis (cell death) 4, 5, 6, 7

The Treatment Process

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, Reducing Viability, Leading to Apoptosis

STEP 1
Cancerous Tumor Located in Breast

STEP 4
Microscopic Cancer Cells are Selectively Targeted with CHCP

The Application of Canady Helios™ Cold Plasma

STEP 1
Cancerous Tumor Located in Breast

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 4
Microscopic Cancer Cells are Selectively Targeted with CHCP

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, Reducing Viability, Leading to Apoptosis

Plasma Videos

What is Plasma
Informational Videos
Cold Plasma Trailer
Canady Hybrid Plasma™ Scalpel – Cutting & Coagulating

THE SCIENCE OF PLASMA PUBLICATIONS

The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer

Jerome Canady, Saravana R. K. Murthy, Taisen Zhuang, Steven Gitelis, Aviram Nissan, Lawan Ly, Olivia Z. Jones, Xiaoqian Cheng, Mohammad Adileh, Alan T. Blank, Matthew W. Colman, Kieth Millikan, Cristina O’Donoghue, Kerstin M. Stenson, Karen Ohara, Gal Schtrechman,...

Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report

Lawan Ly, Xiaoqian Cheng, Saravana R. K. Murthy, Olivia Z. Jones, Taisen Zhuang, Steven Gitelis, Alan T. Blank, Aviram Nissan, Mohammad Adileh, Matthew Colman, Michael Keidar, Giacomo Basadonna and Jerome Canady Soft tissue sarcomas (STS) are a rare and highly...

The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation

Annisa Elbedour, Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, and Jerome CanadyCold atmospheric plasma (CAP) has become a promising tool for modern medicine. With its recent applications in oncology,...

BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer

Saravana R. K. Murthy, Xiaoqian Cheng, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, & Jerome CanadyBreast cancer is the most common cause of cancer death among women worldwide1 and it exhibits diverse molecular features that reflect the...

Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA

Cold atmospheric plasma is a promising adjuvant therapy to selectively combat many cancers, including breast cancer, but not normal tissue; however, the underlying mechanisms remain unexplored. Here, four breast cancer cell lines with different marker status were treated with Canady Helios Cold Plasma™ (CHCP) at various dosages and their differential progress of apoptosis was monitored. Inhibition of cell proliferation, induction of apoptosis, and disruption of the cell cycle were observed. At least 16 histone mRNA types were oxidized and degraded immediately after CHCP treatment by 8-oxoguanine (8-oxoG) modification.